News
OPK
1.300
+2.36%
0.030
OPKO Health Inc <OPK.OQ> expected to post a loss of 9 cents a share - Earnings Preview
OPKO Health Inc expected to post a loss of 9 cents a share. The company is expected to report a fall in quarterly revenue to $182.99 million from $237.6 million a year ago. The Miami Florida-based company will report results on May 1 for the period ending March 31 2024.
Reuters · 3d ago
Weekly Report: what happened at OPK last week (0422-0426)?
Weekly Report · 3d ago
Commit To Buy OPKO Health At $1, Earn 15.2% Annualized Using Options
NASDAQ · 04/24 16:07
Weekly Report: what happened at OPK last week (0415-0419)?
Weekly Report · 04/22 09:13
Weekly Report: what happened at OPK last week (0408-0412)?
Weekly Report · 04/15 09:13
Weekly Report: what happened at OPK last week (0401-0405)?
Weekly Report · 04/08 09:14
Opko Health Buy Rating Backed by Strategic Asset Sale and Promising Oral Drug Candidate
TipRanks · 04/03 10:26
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
NASDAQ · 04/01 17:01
Critical Insights From OPKO Health Analyst Ratings: What You Need To Know
OPKO Health has an average price target of $2.75. The biotechnology company has a 12-month revenue growth rate of -1.85%. The company's market capitalization is below the average for the Health Care sector. OPKO Health is a diversified company that operates in diagnostics and pharmaceuticals.
Benzinga · 04/01 17:00
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
NASDAQ · 04/01 16:42
OPKO Health Is Maintained at Outperform by Barrington Research
Dow Jones · 04/01 16:26
OPKO Health Price Target Maintained With a $1.50/Share by Barrington Research
Dow Jones · 04/01 16:26
Barrington Research Maintains Outperform on OPKO Health, Maintains $1.5 Price Target
Benzinga · 04/01 16:16
OPKO Health Price Target Maintained With a $5.00/Share by Piper Sandler
Dow Jones · 04/01 14:40
Buy Rating Affirmed for Opko Health Amid Strategic Divestiture and Operational Improvement Prospects
TipRanks · 04/01 13:15
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Opko Health (OPK) and Leafly Holdings, Inc. (LFLY)
TipRanks · 04/01 11:10
Weekly Report: what happened at OPK last week (0325-0329)?
Weekly Report · 04/01 09:13
Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear
Laboratory Corporation's shares have been trading around $200 for several years. The company expects growth to return in 2024. LabCorp is the largest laboratory service provider in the world and expects revenue growth in 2023. It has acquired BioReference Health's laboratory testing business for $237 million, adding to its diagnostics segment.
Seeking Alpha · 04/01 06:20
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 03/28 18:08
OPKO Health Stock Rises 16% After Deal to Sell Assets to Labcorp
Shares of OPKO Health rose almost 16% to $1.24 in afternoon trading. The company said it agreed to sell some of its assets to Labcorp for $237.5 million. The stock is still down about 11% from a year ago. Earlier, BioReference Health said it would sell some lab-testing assets to labcorp.
Dow Jones · 03/28 17:54
More
Webull provides a variety of real-time OPK stock news. You can receive the latest news about Opko Health through multiple platforms. This information may help you make smarter investment decisions.
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.